Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| APHP210583 | Other Identifier | Assistance Publique-Hôpitaux de Paris |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Commissariat A L'energie Atomique | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
In image-guided radiotherapy (IGRT), the repeated and increasingly intensive use of on-board positioning imaging, using 2D or 3D Mega-Volt (MV) or kilo-Volt (kV) imaging devices (cone-beam or CBCT scanners), is leading the international medical community to question the potential impact of these additional doses delivered to the patient, especially in at-risk populations such as children and young adults. The doses delivered to the patient by positioning imaging are still relatively unknown, due to the lack of experimental means and software available in clinical routine to easily and accurately evaluate these doses.
The main objective is to estimate by personalized Monte Carlo calculation the physical doses delivered to the patient's organs by the onboard imaging systems during their radiotherapy treatment. The obtained imaging doses will be compared according to different irradiation scenarios commonly used in clinical routine as well as according to the treated location.
The study will consist of 2 successive steps:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lung Neoplasm patients | Lung Neoplasm patients (adults) |
| |
| Pelvic Neoplasm patients | Pelvic Neoplasm patients (adults) |
| |
| Breast Cancer patients | Breast Cancer patients(adults) |
| |
| Ear Nose and Throat (ENT) Cancer patients | Ear Nose and Throat (ENT) Cancer patients (adults) |
| |
| Pediatric Cancer patients | Pediatric cancer patients (under 18 years-old) : neurologic cancer , abdomen cancer, Thorax cancer, Ear Nose and Throat (ENT) Cancer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 3D maps of physical doses | Other | 3D maps of physical doses delivered to organs by positioning imaging will be calculated based on the patient's CT image used by the treatment planning system (dosimetric calculation performed by Monte Carlo method). |
| Measure | Description | Time Frame |
|---|---|---|
| Global analysis of 3D mapping of physical doses delivered to organs by positioning imaging. | Global analysis of 3D mapping of physical doses delivered to organs by positioning imaging. These analyses will aggregate the Doses Volumes Histograms (HDV) by organs of interest as well as the mean dose to 10% (D10), 50% (D50) and 90% (D90) metrics for these same organs to form an individual dosimetric report. | One year after end of data collection |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Female patients (Lung Neoplasm, Breast Cancer, Cancer Ear Nose and Throat / ENT); Male patients (Lung Neoplasm, Pelvic Neoplasm, Cancer Ear Nose and Throat / ENT); Pediatric cancer patients.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexandra BRUNEAU | Contact | 331 44 84 17 12 | alexandra.bruneau@aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Philippe GIRAUD, MD, PhD | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut de Radiothérapie et Radiochirurgie H. Hartmann | Levallois-Perret | Hauts-de-Seine | 92300 | France |
Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared
Two years after the last publication
Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered.
Data sharing must respect the agreements made with funders. Teams wishing obtain IPD must meet the sponsor and IP team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractual agreement.
Processing of shared data must comply with European General Data Protection Regulation (GDPR).
Not provided
Not provided
Not provided
Not provided
Not provided
| Hôpital Henri Mondor - AP-HP | Créteil | Val-de-Marne | 94000 | France |
|
| Institut Gustave Roussy | Villejuif | Val-de-Marne | 94800 | France |
|
| Groupe AMETHYST | Colombes | 92250 | France |
|
| Institut Curie | Paris | 75005 | France |
|
| Hôpital Saint-Louis - AP-HP | Paris | 75010 | France |
|
| Hôpital La Pitié Salpêtrière - AP-HP | Paris | 75013 | France |
|
| Hôpital européen Georges-Pompidou AP-HP | Paris | 75015 | France |
|
| Hôpital Tenon - AP-HP | Paris | 75020 | France |
|
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| D010386 | Pelvic Neoplasms |
| D001943 | Breast Neoplasms |
| D010039 | Otorhinolaryngologic Neoplasms |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D006258 | Head and Neck Neoplasms |
| D010038 | Otorhinolaryngologic Diseases |
Not provided
Not provided